CN101049314A - Dispersion tablet of asiaticoside and preparation method - Google Patents
Dispersion tablet of asiaticoside and preparation method Download PDFInfo
- Publication number
- CN101049314A CN101049314A CN 200610066918 CN200610066918A CN101049314A CN 101049314 A CN101049314 A CN 101049314A CN 200610066918 CN200610066918 CN 200610066918 CN 200610066918 A CN200610066918 A CN 200610066918A CN 101049314 A CN101049314 A CN 101049314A
- Authority
- CN
- China
- Prior art keywords
- asiaticoside
- herba centellae
- total glycosides
- centellae total
- filler
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
A dispersing tablet of asiaticoside is prepared from the asiaticoside and proper auxiliaries. Its preparing process is also disclosed.
Description
Technical field
The present invention relates to a kind of dispersion tablet of asiaticoside and preparation method thereof, belong to technical field of Chinese medicine.
Technical background
Wound, operation wound, burn, keloid and scleroderma are clinical more common diseases, and wherein skin ulcer, keloid, scleroderma and amyloidosis cutis lack satisfied drug treatment.Current people promote the pharmaceutical requirements of wound healing effect constantly to increase the pursuit of quality of life to having.And chemical drugs and biological preparation such as asiaticoside sodium ointment, Contractubex gel, collagenase ointment, lyophilizing M-EGF, external recombinant human epidermal growth factor derivant, bFGF bovine basic fibroblast growth factor, bacillus subtilis active bacteria formulation etc. are this type of disease preparation of treatment, but only limit external mostly, and certain side effect is arranged; And the effect that now commercially available Chinese medicine preparation such as asiaticoside sheet have tangible promotion wound healing, determined curative effect and having no side effect.Herba Centellae (Centella asiatica) is used existing more than 2,000 year history in China as medicinal plants, and domestic aboundresources spreads all over areas to the south, the Yangtze river basin.Just Herba Centellae extract is used as the medicine that promotes wound healing in the seventies in 20th century abroad, through a large amount of clinical verifications, Herba Centellae total glycosides and preparation thereof, external or for oral administration, wound, operation wound, burn, keloid and scleroderma are had good effect, and almost non-toxic, side effect.Right commercially available asiaticoside sheet at present is a conventional tablet, and disintegration time is longer, and onset time is slower, and bioavailability is low, and dosage form falls behind, and the curative effect fluctuation is bigger, and is limited in clinical use.For this reason, develop the very big concern that a kind of bioavailability height, dosage form advanced person, the sure novel dosage form of curative effect just are subjected to medicine enterprise and research and development unit.
For this reason, the character of inventor's bound drug itself and the modern requirement of Chinese medicine preparation, through scientific appraisal, with its be developed as a kind of new quite being subjected to the patient like, bioavailability height, disintegrate dispersible tablet rapidly.By retrieval, this dispersible tablet still belongs to internal blank.
Summary of the invention
Based on asiaticoside sheet good clinical basis and the present deficiency that exists, the object of the present invention is to provide a kind of new pharmaceutical preparation and preparation method thereof, said preparation is longer at the conventional tablet disintegration time, onset time is slower, and bioavailability is hanged down and waited deficiency, is made into the dispersible tablet of the good reputation of Peroral solid dosage form liquid, not only can in cold water, form uniform suspension after the disintegrate fast, directly drink, also can directly swallow or sublingual administration taking convenience; Increased surface area simultaneously, drug release is fast, increases the infiltration rate and the bioavailability of Herba Centellae total glycosides, plays quick-acting and effect efficiently.
The present invention is achieved through the following technical solutions:
A kind of dispersion tablet of asiaticoside, it mainly is prepared from by Herba Centellae total glycosides, disintegrating agent, filler, correctives.Calculate Herba Centellae total glycosides (in asiaticoside) 6-10 part, disintegrating agent 60-80 part, filler 10-34 part, correctives 0.5-2 part according to parts by weight.
Described Herba Centellae total glycosides is commercially available or conventional method makes, and Herba Centellae total glycosides content is not less than 60% in asiaticoside.
Disintegrating agent is selected from one or more of the fine little element of crystallite, carboxymethyl starch sodium, crosslinked carboxymethyl fecula sodium, hyprolose, crospolyvinylpyrrolidone; Filler is selected from one or more in starch, lactose, mannitol, xylitol, calcium sulfate, calcium hydrogen phosphate, the pregelatinized Starch; Correctives is selected from one or more in stevioside, betanin, aspartame, glycyrrhizin, the saccharin sodium.
Preferred disintegrating agent is the fine little element of hyprolose, crystallite; Preferred filler is pregelatinized Starch; Preferred correctives is meant aspartame.
The preparation method of described a kind of dispersion tablet of asiaticoside is: get Herba Centellae total glycosides and disintegrating agent, filler, correctives, pulverize separately becomes fine powder, with the method mix homogeneously that equivalent increases progressively, uses the alcohol granulation of debita spissitudo, drying, and tabletting, promptly.
Specifically, the preparation method of dispersion tablet of asiaticoside is: get Herba Centellae total glycosides (in asiaticoside) 6g, hyprolose 28g, microcrystalline Cellulose 44g, aspartame 1g and pregelatinized Starch are an amount of, pulverize separately becomes fine powder, with the method mix homogeneously that equivalent increases progressively, granulate drying in right amount with 60% ethanol, be pressed into 1000, promptly.
At prior art, Herba Centellae total glycosides has the activation epithelial cell, promotes normal meat dental tissue to form, and accelerates to hinder face and heals rapidly, has the fibrocellular propagation of inhibition, prevents that cicatrix from developing, and makes established cicatrix soften the effect of grade.A large amount of clinical verifications, Herba Centellae total glycosides and preparation thereof, no matter external or for oral administration all has good effect to wound, operation wound, burn, keloid and scleroderma, and almost non-toxic, side effect.It is right because most oral medication belongs to general formulation, exist disintegration time longer, absorb slowly, drawbacks such as bioavailability is low, bound drug character of the present invention and the modern requirement of Chinese medicine preparation are made into the dispersible tablet of the good reputation of Peroral solid dosage form liquid, not only can in cold water, form uniform suspension after the disintegrate fast, directly drink, also can directly swallow or sublingual administration taking convenience; Increased surface area simultaneously, drug release is fast, increases the infiltration rate and the bioavailability of Herba Centellae total glycosides, plays quick-acting and effect efficiently.
The inventor finds that in development process kind, the consumption of adjuvant have considerable influence to it, and for this reason, the applicant has carried out a series of experiments, and is rationally feasible, quality controllable with proof technology of the present invention, to guarantee the beneficial effect of medicine.
Experimental example 1: Study on Forming
1, disintegrating agent screening
According to the characteristics of dispersible tablet with for the requirement of dispersible tablet, in the formulation selection, often select for use the fine little element (MCC) of crystallite, carboxymethyl starch sodium (CMS), hyprolose (L-HPC), crospolyvinylpyrrolidone (PPVP), cross-linking sodium carboxymethyl cellulose (CCNa) etc. as disintegrating agent, below it is examined or check, as follows with 70% ethanol as the wetting agent result.
Table disintegrating agent screening table
| Formula number | Herba Centellae total glycosides | MCC | CMS | L-HPC | PPVP | CCNa | The granule water content | Disintegrate (s) |
| 1 2 3 4 5 6 7 8 9 10 | 8.5 8.5 8.5 8.5 8.5 8.5 8.5 8.5 8.5 8.5 | 70 - - - - 45 - - - 15 | - 70 - - - - 30 - 20 - | - - 70 - - 25 - - 30 35 | - - - 70 - - 40 20 20 - | - - - - 70 - - 50 - 20 | 4.1％ 3.9％ 4.2％ 4.5％ 4.0％ 3.8％ 3.7％ 4.1％ 4.2％ 3.6％ | 176 172 169 150 174 105 127 138 147 100 |
Result of the test shows, above-mentioned various adjuvant disintegration is all in 3 minutes, substantially can both satisfy the disintegrate requirement of dispersible tablet, use separately or be used with other adjuvant and do this type of when test, also can both satisfy the requirement of dispersible tablet, result of the test shows, be used with hyprolose (L-HPC) and microcrystalline Cellulose (MCC), disintegrate is very fast, and dispersed homogeneous degree is better, studies for main adjuvant with hyprolose (L-HPC), the fine little element of crystallite (MCC) for this reason; Filler is selected starch commonly used, lactose, calcium sulfate, pregelatinized Starch etc., and the lactose compressibility is good, but cost is higher, and starch has disintegration, and cheap, selects starch as filler earlier.The result is as follows.
Table prescription screening tables of data (unit; G)
| Name of material | Prescription 11 | Name of material | Prescription 12 | Name of material | Prescription 13 |
| Asiaticoside L-HPC MCC starch 70% ethanol particle water content disintegration (min) hardness (Kg) | 8.5 15 30 46.5 Q.S about 3.8% 2.3 3.5 | Asiaticoside L-HPC MCC starch 70% ethanol particle water content disintegration (min) hardness (Kg) | 8.5 22 30 39.5 Q.S about 3.6% 2.5 4.2 | Asiaticoside L-HPC MCC starch 70% ethanol particle water content disintegration (min) hardness (Kg) | 8.5 28 30 33.5 Q.S about 4.3% 1.9 4.3 |
According to last table result of study as can be known, 13 disintegrates of writing out a prescription are very fast, to the 13 further researchs of writing out a prescription.Through the document inquiry, hyprolose (L-HPC) consumption is 30%, and is bigger, generally should not increase consumption, for this reason, attempt increasing fine little element (MCC) consumption of crystallite, starch is that reference index is screened as the dosage regulator with the disintegration time, and result of study is as follows.
Table prescription screening tables of data (unit: g)
| Name of material | Prescription 14 | Name of material | Prescription 15 |
| Asiaticoside L-HPC MCC starch 70% ethanol particle water content disintegration (min) hardness (Kg) | 8.5 28 37 26.5 Q.S about 3.9% 1.8 4.1 | Asiaticoside L-HPC MCC starch 70% ethanol particle water content disintegration (min) hardness (Kg) | 8.5 28 44 26.5 Q.S about 3.7% 1.5 4.3 |
According to above result of study as can be known, 15 disintegrates of writing out a prescription are very fast, can cross No. 2 sieve after the disintegrate, but disintegrate are fineless and smooth, and the suspendible effect is bad, finds when prescription amplifies that compressibility is not so good, considers filler is screened.Find that simultaneously prescription 15 made granules are comparatively loose, reduce determining alcohol and be 60% and carry out formula optimization that result of study is as follows.
Table prescription screening tables of data (unit: g)
| Prescription 16 | Prescription 17 | Prescription 18 | Prescription 19 | Prescription 20 | Prescription 21 | |
| Asiaticoside L-HPC MCC calcium sulfate calcium monohydrogen phosphate pregelatinized starch lactose sweet mellow wine xylitol grains water content disintegration (s) hardness (Kg) | 8.5 28 44 19.5-----Yue 4.1% 2.3 4.1 | 8.5 28 44 - 19.5 - - - - 2.1 4.0 | 8.5 28 44 - - 19.5 - - - 1.7 4.5 | 8.5 28 44 - - - 19.5 - - 2.5 4.7 | 8.5 28 44 - - - - 19.5 - 2.0 4.3 | 8.5 28 44 - - - - - 19.5 - 2.2 4.2 |
Last table shows that filler selects for use starch, lactose, mannitol, xylitol, calcium sulfate, calcium hydrogen phosphate, pregelatinized Starch can both satisfy the preparation requirement substantially, it is used has carried out trial test simultaneously, also can prepare qualified dispersible tablet; But take all factors into consideration, select for use pregelatinized Starch as filler, obtained granule compressibility is good, and the sheet disintegrate is very fast, and dispersed homogeneous degree is good, the even suspendible of energy after the disintegrate, so preferred pregelatinized Starch is a filler, wetting agent is selected 60% ethanol.
2, correctives consumption screening
In view of Herba Centellae total glycosides in the side is bitter, add the sweeting agent flavoring so adopt, sweeting agent commonly used has: stevioside, betanin, aspartame, glycyrrhizin and saccharin sodium etc.Through trial test, above-mentioned sweeting agent uses separately or is used and can both reach the flavoring purpose to some extent; Result of the test shows that aspartame is a sweeting agent, and not only mouthfeel is good, and can be fit to the use of diabetics simultaneously, so preferred aspartame is a correctives.Below its consumption is screened, as follows.
Table flavoring dosage is preferably shown (unit: g)
| Name of material | Prescription 22 | Name of material | Prescription 23 | Name of material | Prescription 24 |
| Asiaticoside L-HPC MCC pregelatinized starch aspartame 60% ethanol mouthfeel | 10 28 44 18 0.5 Q.S are slightly bitter | Asiaticoside L-HPC MCC pregelatinized starch aspartame 60% ethanol mouthfeel | 10 28 44 18 1.0 Q.S are little sweet | Asiaticoside L-HPC MCC pregelatinized starch aspartame 60% ethanol mouthfeel | 10 28 44 18 2.0 Q.S are sweeter |
Through its consumption examination being found by weight, the aspartame that adds 0.5-2 part can be corrected the bitterness of this medicine, preferred 1.0 parts aspartame is as correctives.
Concrete embodiment
Embodiment 1: Herba Centellae total glycosides 8.76g, hyprolose 28g, microcrystalline Cellulose 44g, aspartame 1.0g, pregelatinized Starch 19.24g
Get the Herba Centellae total glycosides of recipe quantity respectively, hyprolose, microcrystalline Cellulose, aspartame and pregelatinized Starch, pulverize separately becomes fine powder, with the method mix homogeneously that equivalent increases progressively, granulates in right amount with 60% ethanol, and drying is pressed into 1000, promptly.
Embodiment 2: Herba Centellae total glycosides 9g, hyprolose 25g, microcrystalline Cellulose 45g, aspartame 0.5g, lactose 21g
Get the adjuvant in Herba Centellae total glycosides and the prescription respectively, pulverize separately becomes fine powder, with the method mix homogeneously that equivalent increases progressively, granulates in right amount with 70% ethanol, and drying is pressed into 1000, promptly gets dispersible tablet.
Embodiment 3: Herba Centellae total glycosides 8g, hyprolose 28g, carboxymethyl starch sodium 44g, stevioside 1.5g, calcium sulfate 20g
Get the adjuvant in Herba Centellae total glycosides and the prescription respectively, pulverize separately becomes fine powder, with the method mix homogeneously that equivalent increases progressively, granulates in right amount with 50% ethanol, and drying is pressed into 1000, promptly gets dispersible tablet.
Embodiment 4: Herba Centellae total glycosides 7g, microcrystalline Cellulose 28g, carboxymethyl starch sodium 10, crospolyvinylpyrrolidone 35g, mannitol 20g, saccharin sodium 1.0g, glycyrrhizin 0.5g
Get the adjuvant in Herba Centellae total glycosides and the prescription respectively, pulverize separately becomes fine powder, with the method mix homogeneously that equivalent increases progressively, granulates in right amount with 65% ethanol, and drying is pressed into 1000, promptly gets dispersible tablet.
Embodiment 5: Herba Centellae total glycosides 10g, hyprolose 30g, microcrystalline Cellulose 30g, aspartame 2g, xylitol 30g
Get the adjuvant in Herba Centellae total glycosides and the prescription respectively, pulverize separately becomes fine powder, with the method mix homogeneously that equivalent increases progressively, granulates in right amount with 55% ethanol, and drying is pressed into 1000, promptly gets dispersible tablet.
Embodiment 6: Herba Centellae total glycosides 6g, hyprolose 25g, microcrystalline Cellulose 55g, aspartame 0.5g, starch 10g, calcium hydrogen phosphate 4g
Get the adjuvant in Herba Centellae total glycosides and the prescription respectively, pulverize separately becomes fine powder, with the method mix homogeneously that equivalent increases progressively, granulates in right amount with 60% ethanol, and drying is pressed into 1000, promptly gets dispersible tablet.
Embodiment 7: Herba Centellae total glycosides 8g, carboxymethyl starch sodium 30g, crosslinked carboxymethyl fecula sodium 30g, stevioside 0.5g, glycyrrhizin 0.5g, pregelatinized Starch 15g, dextrin 17g
Get the adjuvant in Herba Centellae total glycosides and the prescription respectively, pulverize separately becomes fine powder, with the method mix homogeneously that equivalent increases progressively, granulates in right amount with 60% ethanol, and drying is pressed into 1000, promptly gets dispersible tablet.
Embodiment 8: Herba Centellae total glycosides 6g, crospolyvinylpyrrolidone 80g, xylitol 8g, mannitol 6g
Get the adjuvant in Herba Centellae total glycosides and the prescription respectively, pulverize separately becomes fine powder, with the method mix homogeneously that equivalent increases progressively, granulates in right amount with 70% ethanol, and drying is pressed into 1000, promptly gets dispersible tablet.
Annotate: count by asiaticoside because of the crude drug Herba Centellae total glycosides and be not less than 60%, so the crude drug Herba Centellae total glycosides is converted by actual content when feeding intake.
Claims (7)
1, a kind of dispersion tablet of asiaticoside is characterized in that, it mainly is prepared from by Herba Centellae total glycosides, disintegrating agent, filler, correctives.
2, a kind of dispersion tablet of asiaticoside according to claim 1 is characterized in that, described Herba Centellae total glycosides is commercially available or conventional method makes, and Herba Centellae total glycosides content is not less than 60% in asiaticoside.
3, a kind of dispersion tablet of asiaticoside according to claim 1 is characterized in that, disintegrating agent is selected from one or more of the fine little element of crystallite, carboxymethyl starch sodium, crosslinked carboxymethyl fecula sodium, hyprolose, crospolyvinylpyrrolidone; Filler is selected from one or more in starch, lactose, calcium sulfate, calcium hydrogen phosphate, the pregelatinized Starch; Correctives is selected from one or more in stevioside, betanin, aspartame, glycyrrhizin, the saccharin sodium.
4, a kind of dispersion tablet of asiaticoside according to claim 3 is characterized in that, disintegrating agent is meant hyprolose, the fine little element of crystallite; Filler is meant pregelatinized Starch; Correctives is meant aspartame.
5, according to claim 1,4 described a kind of dispersion tablet of asiaticoside, it is characterized in that, calculate Herba Centellae total glycosides (in asiaticoside) 6-10 part, disintegrating agent 60-80 part, filler 10-34 part, correctives 0.5-2 part according to parts by weight.
6, according to the preparation method of any described a kind of dispersion tablet of asiaticoside among the claim 1-5, it is characterized in that, get Herba Centellae total glycosides and disintegrating agent, filler, correctives, pulverize separately becomes fine powder, with the method mix homogeneously that equivalent increases progressively, use the alcohol granulation of debita spissitudo, drying, tabletting, promptly.
7, the preparation method of a kind of dispersion tablet of asiaticoside according to claim 6, it is characterized in that, get Herba Centellae total glycosides (in asiaticoside) 6g, hyprolose 28g, microcrystalline Cellulose 44g, aspartame 1g and pregelatinized Starch are an amount of, and pulverize separately becomes fine powder, the method mix homogeneously that increases progressively with equivalent, granulate in right amount with 60% ethanol, drying is pressed into 1000, promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610066918A CN101049314B (en) | 2006-04-03 | 2006-04-03 | Dispersion tablet of asiaticoside and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610066918A CN101049314B (en) | 2006-04-03 | 2006-04-03 | Dispersion tablet of asiaticoside and preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101049314A true CN101049314A (en) | 2007-10-10 |
| CN101049314B CN101049314B (en) | 2010-05-12 |
Family
ID=38781050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200610066918A Active CN101049314B (en) | 2006-04-03 | 2006-04-03 | Dispersion tablet of asiaticoside and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101049314B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112891359A (en) * | 2021-03-18 | 2021-06-04 | 海南普利制药股份有限公司 | Asiaticoside tablet |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1672686A (en) * | 2004-03-25 | 2005-09-28 | 一笑堂（湖南）制药有限公司 | Dispersive asiaticoside tablet and its prepn process |
| CN1698668B (en) * | 2004-05-18 | 2010-04-21 | 安徽科创中药天然药物研究所有限责任公司 | Motherwort extract dispersed tablet and preparation method of motherwort extract |
| CN100441201C (en) * | 2005-06-08 | 2008-12-10 | 浙江省医学科学院 | Chinese medicine slow-release formulation containing asiatic pennywort herb water-soluble active ingredient, and its preparing method |
-
2006
- 2006-04-03 CN CN200610066918A patent/CN101049314B/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112891359A (en) * | 2021-03-18 | 2021-06-04 | 海南普利制药股份有限公司 | Asiaticoside tablet |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101049314B (en) | 2010-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3887731B2 (en) | Fibromyalgia treatment | |
| CN102068474A (en) | Capparis spinosa fruit gel ointment, production method thereof, and application thereof to antirheumatic medicaments | |
| CN112353866A (en) | Polypeptide nursing antibacterial gel and preparation method thereof | |
| CN109833412A (en) | A kind of hemorrhoid wet tissue and preparation method thereof | |
| CN101049314A (en) | Dispersion tablet of asiaticoside and preparation method | |
| CN1709302A (en) | Chinese medicine formulation for treating chronic pelvic inflammation and its preparing method | |
| CN1833650A (en) | Jixuedai dispersion tablet having function of promoting wound reunion, and its prepn. method | |
| CN1895623A (en) | Medicinal composition for treating fatty liver, its preparation and use | |
| CN1915369A (en) | Pill for treating whitish and turbid urine of women fungal leucorrhea of dedicatedly | |
| CN1600356A (en) | Combination of Chinese traditional medicine for curing chronic pharyngitis and preparation method | |
| CN1899586A (en) | Chinese medicine preparation for treating gynecologic inflammation and its preparing method | |
| CN1290528C (en) | Medicine for treating toothache | |
| CN1134298A (en) | "Dianxianningxiwan" pills-Chinese patent medicine for epilepsy | |
| CN1864707A (en) | Vaginal effervescence tablet of Ainsliaea fragrans and preparation method thereof | |
| CN1833645A (en) | Huangyangning dispersion tablets and prepn. process | |
| CN100586432C (en) | Yiganling dispersion tablet for treating liver disease and its preparation method | |
| CN1903281A (en) | Traditional Chinese medicine composition for treating urinary system infection | |
| CN1748779A (en) | Medicinal composition for treating chronic prostatitis and its preparation method and use | |
| CN1298351C (en) | Chinese medicine oral preparaton for treating urinary system infestation and its preparation method | |
| CN101057894A (en) | Traditional Chinese medicine preparation for curing gynecologic and its preparation method | |
| CN1186052C (en) | Medicine for treatment of pelvic inflammation, its preparation and preparing method | |
| CN100591335C (en) | Artificial musk oral disintegration tablet for preventing and fast first aid stenocardia and its preparation method | |
| CN1872160A (en) | Sloly released tablet of red sage root, and preparation method | |
| CN1990012A (en) | Three-yellow dispersed tablet | |
| CN1943701A (en) | A kind of medicine for treatment of non-gonococcal urethritis(NGU) and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: BEIJING MINKANG BAOCAO PHARMACEUTICAL TECHNOLOGY CO., LTD. Assignor: Beijing Yinkeruisi Biological Products Research Institute Contract record no.: 2011110000153 Denomination of invention: Dispersion tablet of asiaticoside and preparation method Granted publication date: 20100512 License type: Exclusive License Open date: 20071010 Record date: 20110902 |
|
| CP03 | Change of name, title or address |
Address after: 102200 Beijing Changping District science and Technology Park, 79 battalion road 79, cloud Valley 24, 5 floor, 508 rooms. Patentee after: Beijing Ying Kerui Biological Medicine Research Co Ltd Address before: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee before: Beijing Yinkeruisi Biological Products Research Institute |
|
| CP03 | Change of name, title or address |